Back

CHORUS

Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomized, controlled, non-inferiority trial

Date of Publication:

May 20, 2015

Pubmed Link:
https://pubmed.ncbi.nlm.nih.gov/26002111/
Hypothesis:

Is NACT/IDS non inferior to PDS for women with advanced stage ovarian cancer?

Control Arm(s):

Primary debulking surgery6 cycles of chemotherapy carboplatin AUC 5/6, paclitaxel 175mg/m2 every 3 weeks or other carboplatin doublet or carboplatin single agent

Experimental Arm(s):

3 cycles of chemotherapyinterval debulking surgery3 additional cycles of chemotherapycarboplatin AUC 5/6, paclitaxel 175mg/m2 every 3 weeks or other carboplatin doublet or carboplatin single agent

Primary End Point:

3yr OS (non-inferiority design)

Inclusion Criteria:

stage III or IV ovarian cancer

Exclusion Criteria:

contraindication to PDS or NACT

Results:

PDS (n=276) vs NACT/IDS (n=274):≤1cm residual: 41% vs 73% (SS)median PFS: 12 vs 10.7 mos (NS)3yr OS: 32% vs 34% (NS)median OS: 22.6 vs 24.1 mos (NS) grade 3/4 complications: 24% vs 14% (SS)

Conclusions:

NACT/IDS is not inferior to PDS in advanced stage ovarian cancer patients

Reviewer:
Olga T Filippova